Maria-Victoria Mateos, MD, PhD, of the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discusses the COLUMBA (NCT03277105) study which investigated subcutaneous daratumumab administration in patients with relapsed or refractory multiple myeloma vs. an IV administration. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.